Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.41 |
| ▸ | REN | P00797 | 3/20 | 0.41 |
| ▸ | CTSD | P07339 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.41 |
| ▸ | PDE4A | P27815 | 7/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 3/20 | 0.35 |
| ▸ | PTGES | O14684 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305817 | 0.88 | PDE4D (0.36) | PDE4APDE4BPDE4CPDE4DGRM5 | |
| SCHEMBL4308458 | 0.86 | PDE4D (0.37) | BACE1RENCTSDCYP3A4BACE2 | |
| SCHEMBL4315696 | 0.86 | BACE1 (0.52) | BACE1RENCTSDCYP3A4BACE2 | |
| SCHEMBL4306019 | 0.85 | PDE4D (0.37) | BACE1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4312770 | 0.85 | LMNA (0.41) | PDE4APDE4BPDE4CPDE4DHAO1 | |
| SCHEMBL4566547 | 0.84 | EZH2 (0.36) | BACE1RENCTSDCYP3A4BACE2 | |
| SCHEMBL4306377 | 0.84 | PDE4D (0.38) | BACE1RENCTSDBACE2PDE4A | |
| SCHEMBL4309826 | 0.84 | PDE4D (0.35) | BACE1RENCTSDCYP3A4BACE2 | |
| SCHEMBL4308365 | 0.84 | BACE1 (0.37) | BACE1RENCTSDBACE2PDE4A | |
| SCHEMBL4309481 | 0.83 | PTPN2 (0.36) | BACE1RENCTSDBACE2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885REN 2367/4885CTSD 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.